RIP1 Kinase Inhibitor Compounds for Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with receptor-interacting protein-1 (RIP1) kinase are inadequate, as RIP1 plays a central role in inflammatory diseases and necroptotic cell death, and existing therapies fail to effectively inhibit RIP1.
Innovation Solution
Development of compounds with a specific Formula I structure, which include pharmaceutically acceptable salts, stereoisomers, N-oxides, tautomers, hydrates, solvates, isotopes, and prodrugs, designed to inhibit RIP1 kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat RIP1-associated diseases, then treatment is provided, but the therapies fail to effectively inhibit RIP1 kinase activity
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with specific molecular structures (Formula I) that optimize binding affinity to RIP1 kinase. The compounds feature varied substituent groups (R1-R6, Ra-Re, Rf) and structural parameters (m, n, p) that are systematically modified to enhance inhibitory potency and selectivity against RIP1, directly addressing the insufficient inhibition efficacy of existing therapies
Solution Approach 2:
The patent employs composite materials by creating complex multi-component molecular structures combining heteroaryl rings (ring B), linker groups (L, Z), and various substituent moieties. These composite chemical structures integrate multiple functional groups that work synergistically to achieve effective RIP1 kinase inhibition, overcoming the limitations of simpler existing therapeutic agents
2Reliability
If novel compounds with Formula I structure are developed to inhibit RIP1, then RIP1 kinase inhibition is achieved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a core heteroaryl ring (ring B), linker regions (L and Z), substituent groups (R1-R6), and optional pharmaceutically acceptable components. This modular segmentation allows systematic optimization of each component's contribution to RIP1 binding while maintaining overall molecular manageability and facilitating structure-activity relationship studies
Solution Approach 2:
The patent achieves universality by designing a platform compound structure (Formula I) that can accommodate multiple different substituent variations and pharmacophores while maintaining the core RIP1 inhibition mechanism. This universal scaffold approach enables the development of a series of analogs with optimized properties for different therapeutic applications targeting RIP1-associated diseases
Data Source
AI summary
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.